Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Livio Garattini

Showing results (11-20 of 161) with videos related to

Pageof 17
Sort By:
BMJ (Clinical Research Ed.)|December 13, 2003
Drug sales in four European countries still differSilvio Garattini, Livio Garattini
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 21, 2006
Off-patent drugs in Italy. A short-sighted view?Livio Garattini, Simone Ghislandi
Pharmacoeconomics|December 19, 2019
Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'Livio Garattini, Nicholas Freemantle
Pharmacoeconomics - Open|February 4, 2018
Hospital Pharmacists in Europe: Between Warehouse and Prescription Pad?Livio Garattini, Anna Padula
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 5, 2019
Conflict of interest disclosure: striking a balance?Livio Garattini, Anna Padula
Postgraduate Medicine|November 1, 2017
Pharmaceutical care in Italy and other European countries: between care and commerce?Livio Garattini, Anna Padula
Journal of the Royal Society of Medicine|September 6, 2017
Immunotherapies for advanced melanoma: as promising as they are expensive?Livio Garattini, Anna Padula
Applied Health Economics and Health Policy|August 20, 2017
Multiple Criteria Decision Analysis in Health Technology Assessment for Drugs: Just Another Illusion?Livio Garattini, Anna Padula
Pharmacoeconomics|June 5, 2016
Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?Livio Garattini, Alessandro Curto
Applied Health Economics and Health Policy|August 16, 2014
Comment on: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers"Alessandro Curto, Livio Garattini
Pageof 17

Showing results (11-20 of 161) with videos related to

Sort By:
Pageof 17
BMJ (Clinical Research Ed.)|December 13, 2003
Drug sales in four European countries still differSilvio Garattini, Livio Garattini
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 21, 2006
Off-patent drugs in Italy. A short-sighted view?Livio Garattini, Simone Ghislandi
Pharmacoeconomics|December 19, 2019
Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'Livio Garattini, Nicholas Freemantle
Pharmacoeconomics - Open|February 4, 2018
Hospital Pharmacists in Europe: Between Warehouse and Prescription Pad?Livio Garattini, Anna Padula
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 5, 2019
Conflict of interest disclosure: striking a balance?Livio Garattini, Anna Padula
Postgraduate Medicine|November 1, 2017
Pharmaceutical care in Italy and other European countries: between care and commerce?Livio Garattini, Anna Padula
Journal of the Royal Society of Medicine|September 6, 2017
Immunotherapies for advanced melanoma: as promising as they are expensive?Livio Garattini, Anna Padula
Applied Health Economics and Health Policy|August 20, 2017
Multiple Criteria Decision Analysis in Health Technology Assessment for Drugs: Just Another Illusion?Livio Garattini, Anna Padula
Pharmacoeconomics|June 5, 2016
Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?Livio Garattini, Alessandro Curto
Applied Health Economics and Health Policy|August 16, 2014
Comment on: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers"Alessandro Curto, Livio Garattini
Pageof 17